Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 328

1.

Inhibition of PP2A with LB-100 Enhances Efficacy of CAR-T Cell Therapy Against Glioblastoma.

Cui J, Wang H, Medina R, Zhang Q, Xu C, Indig IH, Zhou J, Song Q, Dmitriev P, Sun MY, Guo L, Wang Y, Rosenblum JS, Kovach JS, Gilbert MR, Zhuang Z.

Cancers (Basel). 2020 Jan 6;12(1). pii: E139. doi: 10.3390/cancers12010139.

2.

Another layer of immune complication in glioblastoma: ICOS-ICOSL.

Terabe M, Gilbert MR.

Neuro Oncol. 2020 Jan 7. pii: noaa001. doi: 10.1093/neuonc/noaa001. [Epub ahead of print] No abstract available.

PMID:
31909413
3.

Vascular Changes in the Retina and Choroid of Patients With EPAS1 Gain-of-Function Mutation Syndrome.

Dmitriev PM, Wang H, Rosenblum JS, Prodanov T, Cui J, Pappo AS, Gilbert MR, Lutty GA, Chan CC, Chew EY, Pacak K, Zhuang Z.

JAMA Ophthalmol. 2019 Dec 26. doi: 10.1001/jamaophthalmol.2019.5244. [Epub ahead of print]

PMID:
31876943
4.

Autocrine BMP4 Signaling Enhances Tumor Aggressiveness via Promoting Wnt/β-Catenin Signaling in IDH1-mutant Gliomas.

Zhou Y, Liu Y, Zhang J, Yu D, Li A, Song H, Zhang W, Davis D, Gilbert MR, Liu F, Yang C.

Transl Oncol. 2019 Dec 19;13(2):125-134. doi: 10.1016/j.tranon.2019.10.019. [Epub ahead of print]

5.

Computational modeling demonstrates that glioblastoma cells can survive spatial environmental challenges through exploratory adaptation.

Celiku O, Gilbert MR, Lavi O.

Nat Commun. 2019 Dec 13;10(1):5704. doi: 10.1038/s41467-019-13726-w.

6.

The association between BMI and BSA-temozolomide-induced myelosuppression toxicities: a correlative analysis of NRG oncology RTOG 0525.

Robins HI, Eickhoff J, Gilbert MR, Armstrong TS, Shi W, De Groot JF, Schultz CJ, Hunter GK, Valeinis E, Roach M 3rd, Youssef EF, Souhami L, Howard SP, Lieberman FS, Herman JG, Zhang P, Mehta MP.

Neurooncol Pract. 2019 Dec;6(6):473-478. doi: 10.1093/nop/npz006. Epub 2019 Apr 6.

PMID:
31832217
7.

Longitudinal molecular trajectories of diffuse glioma in adults.

Barthel FP, Johnson KC, Varn FS, Moskalik AD, Tanner G, Kocakavuk E, Anderson KJ, Abiola O, Aldape K, Alfaro KD, Alpar D, Amin SB, Ashley DM, Bandopadhayay P, Barnholtz-Sloan JS, Beroukhim R, Bock C, Brastianos PK, Brat DJ, Brodbelt AR, Bruns AF, Bulsara KR, Chakrabarty A, Chakravarti A, Chuang JH, Claus EB, Cochran EJ, Connelly J, Costello JF, Finocchiaro G, Fletcher MN, French PJ, Gan HK, Gilbert MR, Gould PV, Grimmer MR, Iavarone A, Ismail A, Jenkinson MD, Khasraw M, Kim H, Kouwenhoven MCM, LaViolette PS, Li M, Lichter P, Ligon KL, Lowman AK, Malta TM, Mazor T, McDonald KL, Molinaro AM, Nam DH, Nayyar N, Ng HK, Ngan CY, Niclou SP, Niers JM, Noushmehr H, Noorbakhsh J, Ormond DR, Park CK, Poisson LM, Rabadan R, Radlwimmer B, Rao G, Reifenberger G, Sa JK, Schuster M, Shaw BL, Short SC, Smitt PAS, Sloan AE, Smits M, Suzuki H, Tabatabai G, Van Meir EG, Watts C, Weller M, Wesseling P, Westerman BA, Widhalm G, Woehrer A, Yung WKA, Zadeh G, Huse JT, De Groot JF, Stead LF, Verhaak RGW; GLASS Consortium.

Nature. 2019 Dec;576(7785):112-120. doi: 10.1038/s41586-019-1775-1. Epub 2019 Nov 20.

PMID:
31748746
8.

Retinoid receptor turnover mediated by sumoylation, ubiquitination and the valosin-containing protein is disrupted in glioblastoma.

Rodriguez V, Bailey R, Larion M, Gilbert MR.

Sci Rep. 2019 Nov 7;9(1):16250. doi: 10.1038/s41598-019-52696-3.

9.

Metabolic Reprogramming Associated with Aggressiveness Occurs in the G-CIMP-High Molecular Subtypes of IDH1mut Lower Grade Gliomas.

Victor RR, Malta TM, Seki T, Lita A, Dowdy T, Celiku O, Cavazos-Saldana A, Li A, Liu Y, Han S, Zhang W, Song H, Davis D, Lee S, Trepel JB, Sabedot TS, Munasinghe J, Yang C, Herold-Mende C, Gilbert MR, Krishna Cherukuri M, Noushmehr H, Larion M.

Neuro Oncol. 2019 Oct 30. pii: noz207. doi: 10.1093/neuonc/noz207. [Epub ahead of print]

PMID:
31665443
10.

Progress in rare central nervous system tumors.

Penas-Prado M, Armstrong TS, Gilbert MR.

Curr Opin Neurol. 2019 Dec;32(6):895-906. doi: 10.1097/WCO.0000000000000755.

PMID:
31577601
11.

Efficient ADCC killing of meningioma by avelumab and a high-affinity natural killer cell line, haNK.

Giles AJ, Hao S, Padget M, Song H, Zhang W, Lynes J, Sanchez V, Liu Y, Jung J, Cao X, Fujii R, Jensen R, Gillespie D, Schlom J, Gilbert MR, Nduom EK, Yang C, Lee JH, Soon-Shiong P, Hodge JW, Park DM.

JCI Insight. 2019 Oct 17;4(20). pii: 130688. doi: 10.1172/jci.insight.130688.

12.

Failure to complete standard radiation therapy in glioblastoma patients: Patterns from a national database with implications for survival and therapeutic decision making in older glioblastoma patients.

Burton E, Yusuf M, Gilbert MR, Gaskins J, Woo S.

J Geriatr Oncol. 2019 Sep 11. pii: S1879-4068(19)30208-5. doi: 10.1016/j.jgo.2019.08.014. [Epub ahead of print]

PMID:
31521589
13.

Mitochondrial NIX Promotes Tumor Survival in the Hypoxic Niche of Glioblastoma.

Jung J, Zhang Y, Celiku O, Zhang W, Song H, Williams BJ, Giles AJ, Rich JN, Abounader R, Gilbert MR, Park DM.

Cancer Res. 2019 Oct 15;79(20):5218-5232. doi: 10.1158/0008-5472.CAN-19-0198. Epub 2019 Sep 5.

PMID:
31488423
14.

Identifying symptom recurrences in primary brain tumor patients using the MDASI-BT and qualitative interviews.

Acquaye AA, Payén SS, Vera E, Williams LA, Gilbert MR, Weathers SP, Armstrong TS.

J Patient Rep Outcomes. 2019 Aug 23;3(1):58. doi: 10.1186/s41687-019-0143-0.

15.

Case-based review: ependymomas in adults.

Cachia D, Johnson DR, Kaufmann TJ, Lowe S, Andersen S, Olar A, Cooper SL, Frankel BM, Gilbert MR.

Neurooncol Pract. 2018 Aug;5(3):142-153. doi: 10.1093/nop/npy026. Epub 2018 Jul 24. Review.

16.

Opportunities and challenges of incorporating clinical outcome assessments in brain tumor clinical trials.

Molinari E, Mendoza TR, Gilbert MR.

Neurooncol Pract. 2019 Mar;6(2):81-92. doi: 10.1093/nop/npy032. Epub 2018 Aug 7. Review.

PMID:
31386029
17.

Toward Single-Organelle Lipidomics in Live Cells.

Lita A, Kuzmin AN, Pliss A, Baev A, Rzhevskii A, Gilbert MR, Larion M, Prasad PN.

Anal Chem. 2019 Sep 3;91(17):11380-11387. doi: 10.1021/acs.analchem.9b02663. Epub 2019 Aug 19.

PMID:
31381322
18.

Targeting hypoxia downstream signaling protein, CAIX, for CAR T-cell therapy against glioblastoma.

Cui J, Zhang Q, Song Q, Wang H, Dmitriev P, Sun MY, Cao X, Wang Y, Guo L, Indig IH, Rosenblum JS, Ji C, Cao D, Yang K, Gilbert MR, Yao Y, Zhuang Z.

Neuro Oncol. 2019 Nov 4;21(11):1436-1446. doi: 10.1093/neuonc/noz117.

PMID:
31276594
19.

Letter: When Less is More: Dexamethasone Dosing for Brain Tumors.

Lim-Fat MJ, Bi WL, Lo J, Lee EQ, Ahluwalia MS, Batchelor TT, Chang SM, Chiocca EA, Chukwueke U, Cloughesy TF, Colman H, Deangelis LM, Galanis E, Gilbert MR, De Groot JF, Lassman AB, Liau LM, Mason W, McFaline-Figueroa JR, Mehta MP, Mellinghoff IK, Nabors LB, Nayak L, Reardon DA, Wen PY.

Neurosurgery. 2019 Sep 1;85(3):E607-E608. doi: 10.1093/neuros/nyz186. No abstract available.

PMID:
31215634
20.

Partnership for defining the impact of 12 selected rare CNS tumors: a report from the CBTRUS and the NCI-CONNECT.

Truitt G, Gittleman H, Leece R, Ostrom QT, Kruchko C, Armstrong TS, Gilbert MR, Barnholtz-Sloan JS.

J Neurooncol. 2019 Aug;144(1):53-63. doi: 10.1007/s11060-019-03215-x. Epub 2019 Jun 17.

PMID:
31209773
21.

Reply to 'Assembling the brain trust: the multidisciplinary imperative in neuro-oncology'.

Aldape K, Brindle KM, Chesler L, Chopra R, Gajjar A, Gilbert MR, Gottardo N, Gutmann DH, Hargrave D, Holland EC, Jones DTW, Joyce JA, Kearns P, Kieran MW, Mellinghoff IK, Merchant M, Pfister SM, Pollard SM, Ramaswamy V, Rich JN, Robinson GW, Rowitch DH, Sampson JH, Taylor MD, Workman P, Gilbertson RJ.

Nat Rev Clin Oncol. 2019 Aug;16(8):522-523. doi: 10.1038/s41571-019-0236-y. No abstract available.

PMID:
31150022
22.

A Transgenic Mouse Model of Pacak⁻Zhuang Syndrome with An Epas1 Gain-of-Function Mutation.

Wang H, Cui J, Yang C, Rosenblum JS, Zhang Q, Song Q, Pang Y, Fang F, Sun M, Dmitriev P, Gilbert MR, Eisenhofer G, Pacak K, Zhuang Z.

Cancers (Basel). 2019 May 14;11(5). pii: E667. doi: 10.3390/cancers11050667.

23.

Challenges to curing primary brain tumours.

Aldape K, Brindle KM, Chesler L, Chopra R, Gajjar A, Gilbert MR, Gottardo N, Gutmann DH, Hargrave D, Holland EC, Jones DTW, Joyce JA, Kearns P, Kieran MW, Mellinghoff IK, Merchant M, Pfister SM, Pollard SM, Ramaswamy V, Rich JN, Robinson GW, Rowitch DH, Sampson JH, Taylor MD, Workman P, Gilbertson RJ.

Nat Rev Clin Oncol. 2019 Aug;16(8):509-520. doi: 10.1038/s41571-019-0177-5. Review.

24.

Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial.

Wen PY, Touat M, Alexander BM, Mellinghoff IK, Ramkissoon S, McCluskey CS, Pelton K, Haidar S, Basu SS, Gaffey SC, Brown LE, Martinez-Ledesma JE, Wu S, Kim J, Wei W, Park MA, Huse JT, Kuhn JG, Rinne ML, Colman H, Agar NYR, Omuro AM, DeAngelis LM, Gilbert MR, de Groot JF, Cloughesy TF, Chi AS, Roberts TM, Zhao JJ, Lee EQ, Nayak L, Heath JR, Horky LL, Batchelor TT, Beroukhim R, Chang SM, Ligon AH, Dunn IF, Koul D, Young GS, Prados MD, Reardon DA, Yung WKA, Ligon KL.

J Clin Oncol. 2019 Mar 20;37(9):741-750. doi: 10.1200/JCO.18.01207. Epub 2019 Feb 4.

25.

Detection of Metabolic Changes Induced via Drug Treatments in Live Cancer Cells and Tissue Using Raman Imaging Microscopy.

Larion M, Dowdy T, Ruiz-Rodado V, Meyer MW, Song H, Zhang W, Davis D, Gilbert MR, Lita A.

Biosensors (Basel). 2018 Dec 28;9(1). pii: E5. doi: 10.3390/bios9010005.

26.

Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 Antagonism.

Prabhu VV, Madhukar NS, Gilvary C, Kline CLB, Oster S, El-Deiry WS, Elemento O, Doherty F, VanEngelenburg A, Durrant J, Tarapore RS, Deacon S, Charter N, Jung J, Park DM, Gilbert MR, Rusert J, Wechsler-Reya R, Arrillaga-Romany I, Batchelor TT, Wen PY, Oster W, Allen JE.

Clin Cancer Res. 2019 Apr 1;25(7):2305-2313. doi: 10.1158/1078-0432.CCR-18-2572. Epub 2018 Dec 17.

PMID:
30559168
27.

MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials.

Hegi ME, Genbrugge E, Gorlia T, Stupp R, Gilbert MR, Chinot OL, Nabors LB, Jones G, Van Criekinge W, Straub J, Weller M.

Clin Cancer Res. 2019 Mar 15;25(6):1809-1816. doi: 10.1158/1078-0432.CCR-18-3181. Epub 2018 Dec 4.

PMID:
30514777
28.

Interreader Variability of Dynamic Contrast-enhanced MRI of Recurrent Glioblastoma: The Multicenter ACRIN 6677/RTOG 0625 Study.

Barboriak DP, Zhang Z, Desai P, Snyder BS, Safriel Y, McKinstry RC, Bokstein F, Sorensen G, Gilbert MR, Boxerman JL.

Radiology. 2019 Feb;290(2):467-476. doi: 10.1148/radiol.2019181296. Epub 2018 Nov 27.

PMID:
30480488
29.

Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma.

Maraka S, Groves MD, Mammoser AG, Melguizo-Gavilanes I, Conrad CA, Tremont-Lukats IW, Loghin ME, O'Brien BJ, Puduvalli VK, Sulman EP, Hess KR, Aldape KD, Gilbert MR, de Groot JF, Alfred Yung WK, Penas-Prado M.

Cancer. 2019 Feb 1;125(3):424-433. doi: 10.1002/cncr.31811. Epub 2018 Oct 25. Erratum in: Cancer. 2019 Apr 15;125(8):1387.

PMID:
30359477
30.

A Revised Diagnostic Classification of Canine Glioma: Towards Validation of the Canine Glioma Patient as a Naturally Occurring Preclinical Model for Human Glioma.

Koehler JW, Miller AD, Miller CR, Porter B, Aldape K, Beck J, Brat D, Cornax I, Corps K, Frank C, Giannini C, Horbinski C, Huse JT, O'Sullivan MG, Rissi DR, Mark Simpson R, Woolard K, Shih JH, Mazcko C, Gilbert MR, LeBlanc AK.

J Neuropathol Exp Neurol. 2018 Nov 1;77(11):1039-1054. doi: 10.1093/jnen/nly085.

31.

Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade.

Lynes J, Jackson S, Sanchez V, Dominah G, Wang X, Kuek A, Hayes CP, Benzo S, Scott GC, Chittiboina P, Zaghloul KA, Park DM, Wu J, Hourigan CS, Giles AJ, Wu T, Maric D, Chen J, Quezado M, Heiss JD, Gilbert MR, Nduom EK.

Neurosurgery. 2019 Apr 1;84(4):945-953. doi: 10.1093/neuros/nyy392.

PMID:
30189044
32.

Heterogeneity within the PF-EPN-B ependymoma subgroup.

Cavalli FMG, Hübner JM, Sharma T, Luu B, Sill M, Zapotocky M, Mack SC, Witt H, Lin T, Shih DJH, Ho B, Santi M, Emery L, Hukin J, Dunham C, McLendon RE, Lipp ES, Gururangan S, Grossbach A, French P, Kros JM, van Veelen MC, Rao AAN, Giannini C, Leary S, Jung S, Faria CC, Mora J, Schüller U, Alonso MM, Chan JA, Klekner A, Chambless LB, Hwang EI, Massimino M, Eberhart CG, Karajannis MA, Lu B, Liau LM, Zollo M, Ferrucci V, Carlotti C, Tirapelli DPC, Tabori U, Bouffet E, Ryzhova M, Ellison DW, Merchant TE, Gilbert MR, Armstrong TS, Korshunov A, Pfister SM, Taylor MD, Aldape K, Pajtler KW, Kool M, Ramaswamy V.

Acta Neuropathol. 2018 Aug;136(2):227-237. doi: 10.1007/s00401-018-1888-x. Epub 2018 Jul 17.

33.

Programmed Death Ligand 1 Is a Negative Prognostic Marker in Recurrent Isocitrate Dehydrogenase-Wildtype Glioblastoma.

Pratt D, Dominah G, Lobel G, Obungu A, Lynes J, Sanchez V, Adamstein N, Wang X, Edwards NA, Wu T, Maric D, Giles AJ, Gilbert MR, Quezado M, Nduom EK.

Neurosurgery. 2019 Aug 1;85(2):280-289. doi: 10.1093/neuros/nyy268.

PMID:
30011045
34.

Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy.

Giles AJ, Hutchinson MND, Sonnemann HM, Jung J, Fecci PE, Ratnam NM, Zhang W, Song H, Bailey R, Davis D, Reid CM, Park DM, Gilbert MR.

J Immunother Cancer. 2018 Jun 11;6(1):51. doi: 10.1186/s40425-018-0371-5.

35.

Pharmacologic inhibition of protein phosphatase-2A achieves durable immune-mediated antitumor activity when combined with PD-1 blockade.

Ho WS, Wang H, Maggio D, Kovach JS, Zhang Q, Song Q, Marincola FM, Heiss JD, Gilbert MR, Lu R, Zhuang Z.

Nat Commun. 2018 May 29;9(1):2126. doi: 10.1038/s41467-018-04425-z.

36.

Immunotherapy in CNS cancers: the role of immune cell trafficking.

Ratnam NM, Gilbert MR, Giles AJ.

Neuro Oncol. 2019 Jan 1;21(1):37-46. doi: 10.1093/neuonc/noy084.

37.

Differentiating pseudoprogression from true progression: analysis of radiographic, biologic, and clinical clues in GBM.

Rowe LS, Butman JA, Mackey M, Shih JH, Cooley-Zgela T, Ning H, Gilbert MR, Smart DK, Camphausen K, Krauze AV.

J Neurooncol. 2018 Aug;139(1):145-152. doi: 10.1007/s11060-018-2855-z. Epub 2018 May 16.

PMID:
29767308
38.

Association of genetic variants with fatigue in patients with malignant glioma.

Armstrong TS, Vera E, Zhou R, Acquaye AA, Sullaway CM, Berger AM, Breton G, Mahajan A, Wefel JS, Gilbert MR, Bondy M, Scheurer ME.

Neurooncol Pract. 2018 May;5(2):122-128. doi: 10.1093/nop/npx020. Epub 2017 Sep 19.

39.

Enhancement of mitochondrial biogenesis and paradoxical inhibition of lactate dehydrogenase mediated by 14-3-3η in oncocytomas.

Feng J, Zhang Q, Li C, Zhou Y, Zhao S, Hong L, Song Q, Yu S, Hu C, Wang H, Mao C, Shepard MJ, Hao S, Dominah G, Sun M, Wan H, Park DM, Gilbert MR, Xu G, Zhuang Z, Zhang Y.

J Pathol. 2018 Jul;245(3):361-372. doi: 10.1002/path.5090. Epub 2018 May 29.

PMID:
29704241
40.

Influence of Residual Disease Following Surgical Resection in Newly Diagnosed Glioblastoma on Clinical, Neurocognitive, and Patient Reported Outcomes.

Hall WA, Pugh SL, Wefel JS, Armstrong TS, Gilbert MR, Brachman DG, Werner-Wasik M, Wendland MM, Brown PD, Chao ST, Roof KS, Robins HI, Mehta MP, Curran WJ Jr, Movsas B.

Neurosurgery. 2019 Jan 1;84(1):66-76. doi: 10.1093/neuros/nyy003.

41.

Prognostic value of contrast enhancement and FLAIR for survival in newly diagnosed glioblastoma treated with and without bevacizumab: results from ACRIN 6686.

Boxerman JL, Zhang Z, Safriel Y, Rogg JM, Wolf RL, Mohan S, Marques H, Sorensen AG, Gilbert MR, Barboriak DP.

Neuro Oncol. 2018 Sep 3;20(10):1400-1410. doi: 10.1093/neuonc/noy049.

42.

Clinical decision making in the era of immunotherapy for high grade-glioma: report of four cases.

Ranjan S, Quezado M, Garren N, Boris L, Siegel C, Lopes Abath Neto O, Theeler BJ, Park DM, Nduom E, Zaghloul KA, Gilbert MR, Wu J.

BMC Cancer. 2018 Mar 1;18(1):239. doi: 10.1186/s12885-018-4131-1.

43.

Relationship between symptom burden and health status: analysis of the MDASI-BT and EQ-5D.

Vera E, Acquaye AA, Mendoza TR, Gilbert MR, Armstrong TS.

Neurooncol Pract. 2018 Mar;5(1):56-63. doi: 10.1093/nop/npx010. Epub 2017 Jul 4.

44.

Short delay in initiation of radiotherapy for patients with glioblastoma-effect of concurrent chemotherapy: a secondary analysis from the NRG Oncology/Radiation Therapy Oncology Group database.

Blumenthal DT, Won M, Mehta MP, Gilbert MR, Brown PD, Bokstein F, Brachman DG, Werner-Wasik M, Hunter GK, Valeinis E, Hopkins K, Souhami L, Howard SP, Lieberman FS, Shrieve DC, Wendland MM, Robinson CG, Zhang P, Corn BW.

Neuro Oncol. 2018 Jun 18;20(7):966-974. doi: 10.1093/neuonc/noy017.

45.

Multidose Botulinum Toxin A for Intralaryngeal Injection: A Cost Analysis.

Gilbert MR, Young VN, Smith LJ, Rosen CA.

J Voice. 2019 Mar;33(2):159-161. doi: 10.1016/j.jvoice.2017.11.004. Epub 2018 Jan 4.

PMID:
29307768
46.

Corrigendum to 'Ependymomas arising outside of the central nervous system: A case series and literature review' [J Clin Neurosci 47 (2018) 202-207].

Yust Katz S, Cachia D, Kamiya-Matsuoka C, Olar A, Theeler B, Penas Prado M, Gilbert MR, Armstrong T.

J Clin Neurosci. 2018 May;51:105. doi: 10.1016/j.jocn.2017.12.011. Epub 2017 Dec 30. No abstract available.

PMID:
29295763
47.

Protein phosphatase 2A inhibition enhances radiation sensitivity and reduces tumor growth in chordoma.

Hao S, Song H, Zhang W, Seldomridge A, Jung J, Giles AJ, Hutchinson MK, Cao X, Colwell N, Lita A, Larion M, Maric D, Abu-Asab M, Quezado M, Kramp T, Camphausen K, Zhuang Z, Gilbert MR, Park DM.

Neuro Oncol. 2018 May 18;20(6):799-809. doi: 10.1093/neuonc/nox241.

48.

Phase I-II clinical trial design: a state-of-the-art paradigm for dose finding.

Yan F, Thall PF, Lu KH, Gilbert MR, Yuan Y.

Ann Oncol. 2018 Mar 1;29(3):694-699. doi: 10.1093/annonc/mdx795.

49.

Novel Targeting of Transcription and Metabolism in Glioblastoma.

Su YT, Chen R, Wang H, Song H, Zhang Q, Chen LY, Lappin H, Vasconcelos G, Lita A, Maric D, Li A, Celiku O, Zhang W, Meetze K, Estok T, Larion M, Abu-Asab M, Zhuang Z, Yang C, Gilbert MR, Wu J.

Clin Cancer Res. 2018 Mar 1;24(5):1124-1137. doi: 10.1158/1078-0432.CCR-17-2032. Epub 2017 Dec 18.

50.

LB-100, a novel Protein Phosphatase 2A (PP2A) inhibitor, sensitizes malignant meningioma cells to the therapeutic effects of radiation.

Ho WS, Sizdahkhani S, Hao S, Song H, Seldomridge A, Tandle A, Maric D, Kramp T, Lu R, Heiss JD, Camphausen K, Gilbert MR, Zhuang Z, Park DM.

Cancer Lett. 2018 Feb 28;415:217-226. doi: 10.1016/j.canlet.2017.11.035. Epub 2017 Dec 2.

Supplemental Content

Loading ...
Support Center